+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Parkinson's Disease Drugs Market by Drug Class, Route of Administration, Age Group: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 251 Pages
  • September 2022
  • Region: Global
  • Allied Market Research
  • ID: 5781819
Description Jump to:
The global Parkinson’s disease drugs market was valued at $5,689.12 million in 2021, and is projected to reach $10,402.65 million by 2031, registering a CAGR of 6.2% from 2021 to 2031.

Parkinson's disease is a slowly progressing neurological condition that affects a few specific nerve cells (neurons) in the substantia nigra region of the brain. These cells produce dopamine, a chemical that transmits the signal in brain. Dopamine is essential for controlling body moves and cause of many Parkinson's disease symptoms is a decrease in dopamine level. People over the age of 50 are mostly affected by Parkinson’s disease. They may further experience mental & behavioral changes, sleep problems, depression, memory difficulties, and fatigue. The Parkinson’s disease drugs are used to treat Parkinson’s disease and reduces the symptoms of Parkinson’s disease. Signs and symptoms of Parkinson’s disease such as tremor, bradykinesia, rigid muscles, impaired posture and balance. Many of the symptoms are due to loss of neurons. The major risk factor is the age and others factors such as environmental factors, heredity, sex, exposure to toxins.

The major key factor such as increase in demand for Parkinson’s disease drugs is anticipated to increase globally during the forecast period, owing to rise in geriatric population and rising prevalence rate of Parkinson’s disease patients. Moreover, an increase in investments by key players toward R&D related to Parkinson’s disease drugs further drive growth of the market globally. However, adverse events associated with therapeutics of Parkinson’s disease drugs and high cost of treatment associated with Parkinson’s disease may limit the market growth. Conversely, high growth potential in untapped emerging countries and increasing R&D and continuous drug approval and product launch of Parkinson’s disease drugs are expected to offer lucrative growth opportunities for the key player in the market.

The Parkinson’s disease drugs market is segmented on the basis of drug class, route of administration, age group and region. On the basis of drug class, the market is classified into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors and others. On the basis of route of administration, it is segmented into oral, injection and transdermal. On the basis of age group, it is segmented into 50 or below 50 and above 50 years. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include AbbVie Inc., Amneal Pharmaceuticals Inc Cantata Bio, Biogen Inc., C.H. Boehringer Sohn Ko. KG, Eli Lilly company, Glaxosmithkline Plc, Gentech Healthcare, Intas Pharmaceuticals Limited, Orion Corporation, Novartis AG, Pfizer Inc., Square group, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Torrent Group, UCB pharma, Viatris Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global spatial genomics and transcriptomics market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of spatial genomics and transcriptomics used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments

By Drug Class

  • Decarboxylase Inhibitors
  • Distribution Channel
  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers
  • Dopamine Agonists
  • COMT Inhibitors
  • MAO-B Inhibitors
  • Others

Route of Administration

  • Oral
  • Injection
  • Transdermal

By Age Group

  • 50 or below 50
  • Above 50 years

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Decarboxylase Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
4.2.4.1 Hospital Pharmacies Market size and forecast, by region
4.2.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
4.2.4.3 Online Providers Market size and forecast, by region
4.3 Dopamine Agonists
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 COMT Inhibitors
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 MAO-B Inhibitors
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Injection
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Transdermal
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP
6.1 Overview
6.1.1 Market size and forecast
6.2 50 or below 50
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Above 50 years
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: PARKINSON'S DISEASE DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.2.1 North America Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
7.2.3 North America Market size and forecast, by Route of Administration
7.2.4 North America Market size and forecast, by Age Group
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Route of Administration
7.2.5.1.3 Market size and forecast, by Age Group
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Route of Administration
7.2.5.2.3 Market size and forecast, by Age Group
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Route of Administration
7.2.5.3.3 Market size and forecast, by Age Group
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.2.1 Europe Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
7.3.3 Europe Market size and forecast, by Route of Administration
7.3.4 Europe Market size and forecast, by Age Group
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Route of Administration
7.3.5.1.3 Market size and forecast, by Age Group
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Route of Administration
7.3.5.2.3 Market size and forecast, by Age Group
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Route of Administration
7.3.5.3.3 Market size and forecast, by Age Group
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Route of Administration
7.3.5.4.3 Market size and forecast, by Age Group
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Route of Administration
7.3.5.5.3 Market size and forecast, by Age Group
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Route of Administration
7.3.5.6.3 Market size and forecast, by Age Group
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.2.1 Asia-Pacific Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
7.4.4 Asia-Pacific Market size and forecast, by Age Group
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Route of Administration
7.4.5.1.3 Market size and forecast, by Age Group
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Route of Administration
7.4.5.2.3 Market size and forecast, by Age Group
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Route of Administration
7.4.5.3.3 Market size and forecast, by Age Group
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Route of Administration
7.4.5.4.3 Market size and forecast, by Age Group
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Route of Administration
7.4.5.5.3 Market size and forecast, by Age Group
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Route of Administration
7.4.5.6.3 Market size and forecast, by Age Group
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.2.1 LAMEA Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
7.5.3 LAMEA Market size and forecast, by Route of Administration
7.5.4 LAMEA Market size and forecast, by Age Group
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Route of Administration
7.5.5.1.3 Market size and forecast, by Age Group
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Route of Administration
7.5.5.2.3 Market size and forecast, by Age Group
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Route of Administration
7.5.5.3.3 Market size and forecast, by Age Group
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Route of Administration
7.5.5.4.3 Market size and forecast, by Age Group
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Amneal Pharmaceuticals, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Biogen Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 C.H. Boehringer Sohn Ko. KG
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Gentech Healthcare
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 GlaxoSmithKline Plc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Intas Pharmaceuticals Limited
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Novartis AG
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Orion Corporation
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Pfizer Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Square group
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Sun Pharmaceutical Industries
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Teva Pharmaceuticals
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Torrent Group
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 UCB
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Viatris Inc.
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
List of Tables
TABLE 1. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR DECARBOXYLASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PARKINSON'S DISEASE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. GLOBAL DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 5. PARKINSON'S DISEASE DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 6. PARKINSON'S DISEASE DRUGS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 7. PARKINSON'S DISEASE DRUGS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR DOPAMINE AGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. PARKINSON'S DISEASE DRUGS MARKET FOR DOPAMINE AGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR COMT INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. PARKINSON'S DISEASE DRUGS MARKET FOR COMT INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR MAO-B INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. PARKINSON'S DISEASE DRUGS MARKET FOR MAO-B INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. PARKINSON'S DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 17. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PARKINSON'S DISEASE DRUGS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR INJECTION, BY REGION, 2021-2031 ($MILLION)
TABLE 20. PARKINSON'S DISEASE DRUGS MARKET FOR INJECTION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR TRANSDERMAL, BY REGION, 2021-2031 ($MILLION)
TABLE 22. PARKINSON'S DISEASE DRUGS MARKET FOR TRANSDERMAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 24. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR 50 OR BELOW 50, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PARKINSON'S DISEASE DRUGS MARKET FOR 50 OR BELOW 50, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 ($MILLION)
TABLE 27. PARKINSON'S DISEASE DRUGS MARKET FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. PARKINSON'S DISEASE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 34. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 36. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 37. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 39. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 40. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 42. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 43. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. EUROPE DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 47. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 48. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 49. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 50. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 51. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 52. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 53. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 54. UK PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 55. UK PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 56. UK PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 57. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 58. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 59. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 60. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 61. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 62. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 71. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 72. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 73. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 74. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 75. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 76. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 77. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 78. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 79. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 81. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 82. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 89. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 90. LAMEA DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 91. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 92. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 93. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 94. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 95. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 96. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 106. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 107. ABBVIE INC.: OPERATING SEGMENTS
TABLE 108. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 109. ABBVIE INC.: NET SALES
TABLE 110. ABBVIE INC.: KEY STRATERGIES
TABLE 111. AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 112. AMNEAL PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 113. AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 114. AMNEAL PHARMACEUTICALS, INC.: NET SALES
TABLE 115. AMNEAL PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 116. BIOGEN INC.: COMPANY SNAPSHOT
TABLE 117. BIOGEN INC.: OPERATING SEGMENTS
TABLE 118. BIOGEN INC.: PRODUCT PORTFOLIO
TABLE 119. BIOGEN INC.: NET SALES
TABLE 120. BIOGEN INC.: KEY STRATERGIES
TABLE 121. C. H. BOEHRINGER SOHN KO. KG: COMPANY SNAPSHOT
TABLE 122. C. H. BOEHRINGER SOHN KO. KG: OPERATING SEGMENTS
TABLE 123. C. H. BOEHRINGER SOHN KO. KG: PRODUCT PORTFOLIO
TABLE 124. C. H. BOEHRINGER SOHN KO. KG: NET SALES
TABLE 125. C. H. BOEHRINGER SOHN KO. KG: KEY STRATERGIES
TABLE 126. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 127. ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 128. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 129. ELI LILLY AND COMPANY: NET SALES
TABLE 130. ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 131. GENTECH HEALTHCARE: COMPANY SNAPSHOT
TABLE 132. GENTECH HEALTHCARE: OPERATING SEGMENTS
TABLE 133. GENTECH HEALTHCARE: PRODUCT PORTFOLIO
TABLE 134. GENTECH HEALTHCARE: NET SALES
TABLE 135. GENTECH HEALTHCARE: KEY STRATERGIES
TABLE 136. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 137. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 138. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 139. GLAXOSMITHKLINE PLC: NET SALES
TABLE 140. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 141. INTAS PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 142. INTAS PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
TABLE 143. INTAS PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 144. INTAS PHARMACEUTICALS LIMITED: NET SALES
TABLE 145. INTAS PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 146. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 147. NOVARTIS AG: OPERATING SEGMENTS
TABLE 148. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 149. NOVARTIS AG: NET SALES
TABLE 150. NOVARTIS AG: KEY STRATERGIES
TABLE 151. ORION CORPORATION: COMPANY SNAPSHOT
TABLE 152. ORION CORPORATION: OPERATING SEGMENTS
TABLE 153. ORION CORPORATION: PRODUCT PORTFOLIO
TABLE 154. ORION CORPORATION: NET SALES
TABLE 155. ORION CORPORATION: KEY STRATERGIES
TABLE 156. PFIZER INC.: COMPANY SNAPSHOT
TABLE 157. PFIZER INC.: OPERATING SEGMENTS
TABLE 158. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 159. PFIZER INC.: NET SALES
TABLE 160. PFIZER INC.: KEY STRATERGIES
TABLE 161. SQUARE GROUP: COMPANY SNAPSHOT
TABLE 162. SQUARE GROUP: OPERATING SEGMENTS
TABLE 163. SQUARE GROUP: PRODUCT PORTFOLIO
TABLE 164. SQUARE GROUP: NET SALES
TABLE 165. SQUARE GROUP: KEY STRATERGIES
TABLE 166. SUN PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 167. SUN PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
TABLE 168. SUN PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 169. SUN PHARMACEUTICAL INDUSTRIES: NET SALES
TABLE 170. SUN PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
TABLE 171. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 172. TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 173. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 174. TEVA PHARMACEUTICALS: NET SALES
TABLE 175. TEVA PHARMACEUTICALS: KEY STRATERGIES
TABLE 176. TORRENT GROUP: COMPANY SNAPSHOT
TABLE 177. TORRENT GROUP: OPERATING SEGMENTS
TABLE 178. TORRENT GROUP: PRODUCT PORTFOLIO
TABLE 179. TORRENT GROUP: NET SALES
TABLE 180. TORRENT GROUP: KEY STRATERGIES
TABLE 181. UCB: COMPANY SNAPSHOT
TABLE 182. UCB: OPERATING SEGMENTS
TABLE 183. UCB: PRODUCT PORTFOLIO
TABLE 184. UCB: NET SALES
TABLE 185. UCB: KEY STRATERGIES
TABLE 186. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 187. VIATRIS INC.: OPERATING SEGMENTS
TABLE 188. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 189. VIATRIS INC.: NET SALES
TABLE 190. VIATRIS INC.: KEY STRATERGIES
List of Figures
FIGURE 1. PARKINSON'S DISEASE DRUGS MARKET SEGMENTATION
FIGURE 2. PARKINSON'S DISEASE DRUGS MARKET, 2021-2031
FIGURE 3. PARKINSON'S DISEASE DRUGS MARKET, 2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5. PORTER FIVE-1
FIGURE 6. PORTER FIVE-2
FIGURE 7. PORTER FIVE-3
FIGURE 8. PORTER FIVE-4
FIGURE 9. PORTER FIVE-5
FIGURE 10. TOP PLAYER POSITIONING
FIGURE 11. PARKINSON'S DISEASE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12. PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DOPAMINE AGONISTS PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMT INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MAO-B INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 18. PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ORAL PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF INJECTION PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF TRANSDERMAL PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 22. PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021 (%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF 50 OR BELOW 50 PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF ABOVE 50 YEARS PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 (%)
FIGURE 25. PARKINSON'S DISEASE DRUGS MARKET BY REGION, 2021
FIGURE 26. U.S. PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 27. CANADA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 28. MEXICO PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 29. GERMANY PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 30. FRANCE PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 31. UK PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 32. ITALY PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 33. SPAIN PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 34. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 35. JAPAN PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 36. CHINA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 37. INDIA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 38. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 39. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 41. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 42. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 43. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 44. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 51. ABBVIE INC..: NET SALES , ($MILLION)
FIGURE 52. AMNEAL PHARMACEUTICALS, INC..: NET SALES , ($MILLION)
FIGURE 53. BIOGEN INC..: NET SALES , ($MILLION)
FIGURE 54. C. H. BOEHRINGER SOHN KO. KG.: NET SALES , ($MILLION)
FIGURE 55. ELI LILLY AND COMPANY.: NET SALES , ($MILLION)
FIGURE 56. GENTECH HEALTHCARE.: NET SALES , ($MILLION)
FIGURE 57. GLAXOSMITHKLINE PLC.: NET SALES , ($MILLION)
FIGURE 58. INTAS PHARMACEUTICALS LIMITED.: NET SALES , ($MILLION)
FIGURE 59. NOVARTIS AG.: NET SALES , ($MILLION)
FIGURE 60. ORION CORPORATION.: NET SALES , ($MILLION)
FIGURE 61. PFIZER INC..: NET SALES , ($MILLION)
FIGURE 62. SQUARE GROUP.: NET SALES , ($MILLION)
FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES.: NET SALES , ($MILLION)
FIGURE 64. TEVA PHARMACEUTICALS.: NET SALES , ($MILLION)
FIGURE 65. TORRENT GROUP.: NET SALES , ($MILLION)
FIGURE 66. UCB.: NET SALES , ($MILLION)
FIGURE 67. VIATRIS INC..: NET SALES , ($MILLION)

Executive Summary

According to the report titled, “Parkinson’s Disease Drugs, by Drug class, Route of administration, Age group: Global Opportunity Analysis and Industry Forecast, 2021-2031," the global Parkinson’s disease market was valued at $5,689.12 million in 2021 and is projected to reach $10,402.65 million by 2031 registering a CAGR of 6.2% from 2021 to 2031.

Parkinson’s disease affects neurological system and areas of body that are under the control of nerves. Parkinson’s disease is a neurodegenerative disease that mostly occurs above age of 50. Parkinson’s disease is also called as neurodegenerative disease or idiopathic Parkinsonism. The substantia nigra is a region of the brain where dopamine is produced and when cells of this part begin to die, it leads to Parkinson's disease. Thus, dopamine level is decreased in Parkinson’s disease patients.

The major key factors that drive the Parkinson's disease drugs market size is increase in prevalence of Parkinson’s disease. In addition, rise in R&D pipeline products and surge in demand for Parkinson’s disease drugs are further expected to boost the market growth during forecast period. Moreover, availability of wide range of Parkinson’s disease drugs and increase in geriatric population in developed countries are some Parkinson's disease drugs market trends further propels growth of market.

However, high-cost of treatment associated with Parkinson’s disease hamper growth of the Parkinson’s disease drugs market during the forecast period. Conversely, the ongoing medicine approvals and product launch of Parkinson’s disease drugs are expected to provide numerous opportunities during Parkinson's disease drugs market forecast.

COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The global Parkinson’s disease drugs market also declined in 2020 due to global economic recession led by COVID-19. However, Parkinson's disease drugs industry witness recovery in the year 2021, owing to increase in adoption of Parkinson’s disease drugs and rise in R&D pipeline products of Parkinson’s disease drugs.

The global Parkinson’s disease drugs market is segmented on the basis of drug class, route of administration, age group and region. By drug class, decarboxylase inhibitors, dopamine agonist, COMT inhibitors, MAO-B inhibitors and others. The decarboxylase inhibitors segment was the major revenue contributor in 2021, during the forecast period, owing to the surge in the high adoption of Parkinson’s disease drugs and increase in geriatric population as geriatric population more prone to Parkinson’s disease are the driving factor accelerating the growth of the decarboxylase inhibitors segment.

However, COMT inhibitor is projected to exhibit the fastest market growth during the forecast period due to rise in the R&D of pipeline products of COMT inhibitors is anticipated to fuel the growth of the market.

By route of administration, the market is segmented into oral, injection, and transdermal. The oral segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to advantages associated with oral routes such as easy to administer drugs and pain free.

On the basis of age group, the market is divided into 50 or below 50 and above 50 years. The above 50 years segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period, owing to increase in geriatric population which are more prone to Parkinson’s disease.

By region, the Parkinson’s disease drugs market are studied across North America, Asia-Pacific, Europe, and LAMEA. North America accounted for the largest Parkinson’s disease drugs market share in 2021, and is expected to remain dominant throughout the forecast period. This is attributed to factors such as availability of treatments for Parkinson’s disease, well-established regulations for approval and distribution of products & services. In addition, availability of wide range of Parkinson’s disease drugs and increase in geriatric population in this region propels growth of market.

However, Asia-Pacific is projected to register the highest CAGR of 8.8% during the forecast period, owing to increase in geriatric population. In addition, greater emphasis on research and development activities by both public and commercial organizations for the creation of innovative treatments for Parkinson's disease further drive growth of the region.

According to Onkar Sumant, Manager, Healthcare of the research firm, “rise in adoption of Parkinson’s disease drugs owing to increase in prevalence of Parkinson’s disease patients. In addition, rise in R&D pipeline products and surge in demand for Parkinson’s disease drugs are expected to boost the market growth during forecast period. Moreover, availability of wide range of Parkinson’s disease drugs and increase in geriatric population in developed countries propels growth of market.”

Key Findings of the Study

  • Based on drug class, the decarboxylase inhibitors held largest market share in the global market in 2021. However, COMT inhibitors are anticipated to grow at the highest CAGR of 9.0% during Parkinson’s disease drugs market analysis.
  • Based on route of administration, the oral segment held largest market share in 2021 and is expected to remain dominant throughout the forecast period.
  • By age group, the above 50 years segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period.
  • Based on Region, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 8.8% during the forecast period.

Companies Mentioned

  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc.
  • C.H. Boehringer Sohn Ko. KG
  • Eli Lilly and Company
  • Gentech Healthcare
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Limited
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Square group
  • Sun Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Torrent Group
  • UCB
  • Viatris Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages251
PublishedSeptember 2022
Forecast Period2021 - 2031
Estimated Market Value ( USD ) in 2021 $ 5689.12 million
Forecasted Market Value ( USD ) by 2031 $ 10402.65 million
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Anti-Parkinson Drugs Global Market Report 2024 - Product Image

Anti-Parkinson Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Parkinson's Disease Treatment Market Analysis & Forecast to 2024-2034 - Product Image

Parkinson's Disease Treatment Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Parkinson's Disease Market by Drug Class, by Medical Devices Devices, by Route of Administration, by Distribution Channel, and by Region - Product Image

Parkinson's Disease Market by Drug Class, by Medical Devices Devices, by Route of Administration, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Parkinson's disease - Pipeline Insight, 2024 - Product Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • 230 Pages
  • Global
From
Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 285 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.